{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Occurrence of pre-defined AEs', '-', 'Occurrence and relationship to vaccination of any', 'pIMDs during the entire study period in all subjects.', 'Humoral Immunogenicity of the study vaccine in subset', 'of subjects from ZOSTER-006 and ZOSTER-022.', '-', 'Anti-gE and anti-VZV Ab concentrations as', 'determined by Enzyme-linked Immunosorbent Assay', '(ELISA), in a subset of subjects at Months 0, 3, 14,', '26 and 38.', 'Tertiary', 'Cell-mediated immunogenicity (CMI) of the study', 'vaccine in subsets of subjects from ZOSTER-006 only.', '-', 'CMI in terms of frequencies of antigen-specific CD4', 'T cells at Months 0, 3, 14, 26 and 38', '-', 'Frequencies of CD4 T cells with antigen-specific', 'Interferon gamma (IFN-y) and/or Interleukin-2 (IL-', '2) and/or Tumour Necrosis Factor alpha (TNF-a)', 'and/or CD40 Ligand (CD40L) secretion/expression', 'to glycoprotein E (gE) and VZV as determined by', 'intracellular cytokine staining (ICS) in a subset of', 'subjects at Months 0, 3, 14, 26 and 38.', '11-FEB-2019', '12', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'TABLE OF CONTENTS', 'PAGE', 'SYNOPSIS', '9', 'LIST OF ABBREVIATIONS', '18', 'GLOSSARY OF TERMS', '19', '1. INTRODUCTION', '21', '1.1.', 'Background', '21', '1.1.1.', 'Risk factors for herpes zoster', '21', '1.1.2', 'ZOSTER-006 and ZOSTER-022', '22', '1.2.', 'Rationale for the study', '22', '2.', 'BENEFIT: RISK ASSESSMENT', '23', '3. OBJECTIVES', '23', '3.1.', 'Primary Objective', '23', '3.2.', 'Secondary Objectives', '23', '3.3.', 'Tertiary Objectives', '23', '4.', 'STUDY DESIGN OVERVIEW', '24', '4.1.', 'Discussion of study design', '24', '5.', 'HZ CASE DEFINITION', '24', '6. STUDY POPULATION', '25', '6.1.', 'Number of subjects/ centres', '25', '6.2.', 'Inclusion criteria for the study', '25', '6.2.1.', 'Inclusion criteria for the study data encoding', '25', '6.3.', 'Exclusion criteria for the study', '26', '6.3.1.', 'Exclusion criteria for data encoding', '26', '7. CONDUCT OF THE STUDY', '26', '7.1.', 'Regulatory and ethical considerations', '26', '7.2.', 'Informed consent', '26', '8.', 'DETAILED STUDY PROCEDURES', '27', '8.1.', 'Subject identification', '27', '8.2.', 'Outline of study procedures', '28', '8.3.', 'Detailed description of study procedures', '28', '8.3.1.', 'Check inclusion and exclusion criteria', '28', '8.3.2.', 'Encoding of data in the ZOSTER-064 eCRF', '28', '8.3.2.1.', 'Demographic characteristics', '28', '8.3.3.', 'Encoding of QoL questionnaires', '29', '8.3.4.', 'Study conclusion', '29', '8.4.', 'Biological sample handling and analysis', '29', '9. SAFETY', '29', '10. DATA EVALUATION: CRITERIA FOR EVALUATION OF OBJECTIVES', '29', '11-FEB-2019', '13', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', '10.1.', 'Primary endpoint', '29', '10.2.', 'Secondary endpoints', '29', '10.3.', 'Tertiary endpoints', '30', '10.4.', 'Determination of sample size', '31', '10.4.1. Number of subjects in the CMI subset', '31', '10.4.2.', 'Number of subjects in the Humoral subset', '31', '10.5.', 'Cohorts for Analysis', '31', '10.5.1.', 'Total Vaccinated cohort', '31', '10.5.2.', 'modified Total Vaccinated Cohort', '32', '10.5.3.', 'According to Protocol cohort for analysis of', 'immunogenicity', '32', '10.6.', 'Derived and transformed data', '33', '10.6.1.', 'Handling of missing data', '33', '10.6.2.', 'Humoral and CMI immune response', '34', '10.7.', 'Statistical methods', '34', '10.7.1.', 'Quality of Life Questionnaires', '34', '10.7.2.', 'SF-36 questionnaire', '34', '10.7.3.', 'EQ-5D questionnaire', '35', '10.7.4.', 'Definition of Frailty', '35', '10.7.5.', 'HZ burden-of-illness score', '37', '10.7.6.', 'Analysis of Frailty', '37', '10.7.6.1. Analysis of primary objective', '37', '10.7.6.2.', 'Analysis of secondary objectives', '37', '10.7.6.2.1. Vaccine efficacy against HZ by', 'frailty status', '37', '10.7.6.2.2. Vaccine efficacy against HZ BOI', 'by frailty status', '38', '10.7.6.3. Predictive factors for individuals developing HZ', '38', '10.7.6.4.', 'Analysis of safety by frailty status', '39', '10.7.7.', 'Analysis of immunogenicity', '39', '10.7.7.1.', 'Humoral immune response', '39', '10.7.7.2. Cell-mediated immune response', '39', '10.8. Interpretation of analyses', '40', '10.9.', 'Conduct of analyses', '40', '10.9.1.', 'Sequence of analyses', '40', '10.9.2.', 'Statistical considerations for interim analyses', '40', '11. ADMINISTRATIVE MATTERS', '41', '11.1. Electronic Case Report Form instructions', '41', '11.2.', 'Study monitoring by GSK Biologicals', '41', '11.3.', 'Record retention', '42', '11.4.', 'Quality assurance', '43', '11.5.', 'Posting of information on publicly available registers and publication', 'policy', '43', '11.6.', 'Provision of study results to investigators', '43', '12. COUNTRY SPECIFIC REQUIREMENTS', '44', '12.1. Requirements for Japan', '44', '12.1.1. Regulatory and Ethical Considerations', '44', '12.1.2.', 'Study period', '44', '12.1.3.', 'Study administrative structure', '44', '11-FEB-2019', '14', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}